ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,770.20
      0.55%
      US Tech 100
      19,636.04
      0.55%
      Dow Jones
      42,801.72
      0.52%
      Brent Oil
      70.235
      0.00%
      Bitcoin
      83,327.68
      -3.28%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE

      6. GSK plc (GSK) Quote

      GSK plc

      GSK plc (GSK)

      Goldseek Resources Inc
      Gsk Plc
      40.05
      0.75
      (1.91%)
      Closed March 09 4:00PM
      Delayed by 15 minutes
      40.05
      0.00
      (0.00%)
      After Hours: 7:15PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      40.05
      Bid
      -
      Ask
      -
      Volume
      8,122,546
      39.48 Day's Range 40.59
      31.715 52 Week Range 45.925
      Market Cap
      83.023B
      Previous Close
      39.30
      Open
      39.50
      Last Trade
      1
      @
      40.1
      Last Trade Time
      Financial Volume
      $ 325,401,157
      VWAP
      40.0615
      Average Volume (3m)
      4,651,892
      Shares Outstanding
      2,072,972,741
      Dividend Yield
      4.00%
      PE Ratio
      12.35
      Earnings Per Share (EPS)
      1.24
      Revenue
      31.38B
      Net Profit
      2.58B

      About GSK plc

      In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines.

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.gsk.com
      Headquarters
      London, Gbr
      Founded
      -
      GSK plc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker GSK. The last closing price for GSK was $39.30. Over the last year, GSK shares have traded in a share price range of $ 31.715 to $ 45.925.

      GSK currently has 2,072,972,741 shares outstanding. The market capitalization of GSK is $81.47 billion. GSK has a price to earnings ratio (PE ratio) of 12.35.

      Ask ADVFN Intelligence (AI)

      GSK (GSK) Options Flow Summary

      GSK Options Flow

      Overall Flow

      Bullish

      Net Premium

      87k

      Calls / Puts

      200.00%

      Buys / Sells

      200.00%

      OTM / ITM

      50.00%

      Sweeps Ratio

      0.00%

      GSK Latest News

      More News

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      March 07 2025
      GSK (1.91%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      February 27 2025
      GSK (1.91%)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
      Edgar (US Regulatory)
      February 27 2025
      GSK (1.91%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      12.416.4027630180737.6440.0537.1509496610938.37936779DR
      43.569.7560975609836.4940.0535.53528473337.27439075DR
      126.0317.724867724934.0240.0531.715465189235.5215607DR
      26-3.57-8.1843191196743.6244.1931.715521475936.61146998DR
      52-3.63-8.3104395604443.6845.92531.715428979838.62413278DR
      1560.370.93245967741939.6846.9728.465445571037.66554177DR
      260-0.95-2.317073170734146.9728.465444961738.23420115DR

      GSK - Frequently Asked Questions (FAQ)

      What is the current GSK share price?
      The current share price of GSK is $ 40.05
      How many GSK shares are in issue?
      GSK has 2,072,972,741 shares in issue
      What is the market cap of GSK?
      The market capitalisation of GSK is USD 81.47B
      What is the 1 year trading range for GSK share price?
      GSK has traded in the range of $ 31.715 to $ 45.925 during the past year
      What is the PE ratio of GSK?
      The price to earnings ratio of GSK is 12.35
      What is the cash to sales ratio of GSK?
      The cash to sales ratio of GSK is 1.01
      What is the reporting currency for GSK?
      GSK reports financial results in GBP
      What is the latest annual turnover for GSK?
      The latest annual turnover of GSK is GBP 31.38B
      What is the latest annual profit for GSK?
      The latest annual profit of GSK is GBP 2.58B
      What is the registered address of GSK?
      The registered address for GSK is 79 NEW OXFORD STREET, LONDON, WC1A 1DG
      What is the GSK website address?
      The website address for GSK is www.gsk.com
      Which industry sector does GSK operate in?
      GSK operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      PNSTPinstripes Holdings Inc
      $ 0.102
      (115.64%)
      		464.13k
      WLYBJohn Wiley and Sons Inc
      $ 44.79
      (19.92%)
      		161
      AMRCAmeresco Inc
      $ 11.08
      (19.27%)
      		1.97M
      GAPGap Inc
      $ 23.15
      (18.84%)
      		30.17M
      KUKEKuke Music Holding Limited
      $ 0.2273
      (18.57%)
      		3.35M
      BBAIBigBear ai Holdings Inc
      $ 3.37
      (-19.76%)
      		77.69M
      GCOGenesco Inc
      $ 27.13
      (-16.27%)
      		1.21M
      IOTSamsara Inc
      $ 35.38
      (-15.52%)
      		13.09M
      EVCEntravision Communications Corp
      $ 1.76
      (-15.38%)
      		1.41M
      AKAaka Brands Holding Corp
      $ 13.40
      (-11.90%)
      		17.92k
      FFord Motor Company
      $ 9.895
      (2.97%)
      		150.64M
      HPEHewlett Packard Enterprise Co
      $ 16.011
      (-10.85%)
      		81.95M
      BBAIBigBear ai Holdings Inc
      $ 3.37
      (-19.76%)
      		78.65M
      NUNu Holdings Ltd
      $ 10.815
      (1.55%)
      		63.83M
      BTEBaytex Energy Corporation
      $ 2.03
      (3.05%)
      		57.91M

      GSK Discussion

      View Posts
      Monksdream Monksdream 6 months ago
      GSK up and down but mostly up
      👍️0
      Monksdream Monksdream 1 year ago
      GSK new 52 week high
      👍️0
      Monksdream Monksdream 1 year ago
      GSK new 52 week high
      👍️0
      Monksdream Monksdream 1 year ago
      GSK new 52 week high
      👍️ 1
      1jas 1jas 2 years ago
      has anybody here seen that enzolytics pharm announced that they have a cure for hiv/aids yesterday.
      👍️0
      MrHankey MrHankey 2 years ago
      Does the name Christian Lamarco (www.culperresearch.com) mean anything to you?
      If not, you should know that this "activist investor" (aka "short") has requested through FOIA from the FDA for the below information. Prepare for a hit piece and a stock drop.

      "Requesting copies of the letter and/or all communications from the FDA to GSK requesting the withdrawal of GSK's Blenrep from the market in the US, as widely reported in November 2022."

      https://www.fda.gov/media/170006/download
      👍️0
      Magnum7419 Magnum7419 2 years ago
      i am in 100@ 34.56 :)
      👍️0
      Magnum7419 Magnum7419 2 years ago
      GSK #1 pick!!
      👍️0
      jondoeuk jondoeuk 2 years ago
      Post hoc analysis shows that biomarker correlates with response to NY-ESO-1 TCR-T cells in patients with synovial sarcoma https://www.nature.com/articles/s41467-022-32491-x
      👍️0
      BottomBounce BottomBounce 3 years ago
      $GSK Total Debt is $22.11 Billion // $8.00 should be trading
      👍️0
      rosemountbomber rosemountbomber 3 years ago
      Anyone know how we will calculate our cost basis in Haleon?
      👍️0
      ruke ruke 3 years ago
      So, why shares aren't realy mooning in pre-market? Isn't that strange?
      👍️0
      jondoeuk jondoeuk 3 years ago
      Complete Responses in 100% of dMMR Rectal Cancer With Neoadjuvant PD-1 Inhibition https://www.medpagetoday.com/meetingcoverage/asco/99071
      👍️0
      jondoeuk jondoeuk 3 years ago
      Lete-Cel ASCO data https://www.cgtlive.com/view/lete-cel-exhibits-anti-tumor-activity-long-median-pfs-patients-myxoid-round-cell-liposarcoma

      👍️0
      jondoeuk jondoeuk 3 years ago
      The company has updated the master protocol for their next generation constructs to include a third arm with GSK4427296 https://clinicaltrials.gov/ct2/show/NCT04526509

      This uses LYEL's Epi-R https://lyell.com/our-platforms
      👍️0
      4MVault 4MVault 3 years ago
      GSK Should buy ATOS
      👍️0
      jondoeuk jondoeuk 4 years ago
      New NY-ESO-1 TCR-T data https://jitc.bmj.com/content/7/1/276

      From it: ''These data provide an initial rationale as to how tumors with histologies resistant to checkpoint blockade can be successfully targeted with adoptive T-cell therapy. Furthermore, these data are the first to demonstrate successful infiltration of solid tumors by SPEAR T cells, which are able to kill tumor cells. Our data also suggest that antigen loss or alterations in the expression of antigen processing proteins are not primary mechanisms of resistance. Moreover, the therapeutic efficacy may be enhanced through use of a high dose fludarabine-containing preparative lymphodepletion regimen, by promoting greater engraftment at the tumor site, and through modulation of TAM.''
      👍️0
      jondoeuk jondoeuk 4 years ago
      They have shared some preclinical data https://www.sec.gov/Archives/edgar/data/1806952/000119312521172500/d168165ds1.htm
      👍️0
      jondoeuk jondoeuk 4 years ago
      Preclinical data from another group: ''Hepatocellular carcinoma (HCC) is responsible for most of primary liver cancer cases and is the sixth most common cancer in the world with a general 5 year survival rate of 18% due to lack of effective therapy. Adoptive T-cell therapy (ACT) with T-cell receptor–engineered T-cell (TCR-T) against HCC-associated antigen a-fetoprotein (AFP), can redirect human T cells to recognize and kill HCC tumor cells.

      However, the clinical efficacy of TCR-T therapy is dependent on the proper expansion, in vivo persistence of T cells that is markedly reduced due to exhaustion-associated dysfunction, and activation induced cell death. To improve persistence of TCR-T cells without modifying TCR affinity, we engineered TCR-T cells to overexpress c-Jun, an AP-1 transcription factor associated with T cell development and activation. In this study, we showed that TCR-T cells overexpressing c-Jun have enhanced expansion capacity in culture, improved cytokine production against HepG2 tumor cells without altering their cytotoxic potential.

      Interestingly TCR-T cells overexpressing c-Jun showed resistance to activation induced cell death with decreased expression of inhibitory receptors after stimulation with HepG2 tumor cells. Thus, c-Jun overexpression could be a potential therapeutic agent to enhance the anti-tumor efficacy of TCR-T cells against HCC.''

      https://virtual.aai.org/aai/2021/virtual-immunology-2021/317351/mohamed.hussein.the.role.of.c-jun.in.enhancing.tcr-t.function.in.treatment.of.html
      👍️0
      jondoeuk jondoeuk 4 years ago
      Some more info https://lyell.com/our-platforms

      👍️0
      stillness0007 stillness0007 4 years ago
      GSK V TEVA question. The panel of judges heard the case on Feb 23rd. Am I right to understand, usually a decision is made 3-4 months after that? Cause some are saying by end of 2022, which makes no sense to me.
      👍️0
      testing4covid testing4covid 4 years ago
      Achiko AG: The One Ecosystem that Takes a ‘Swiss Cheese’ Approach to COVID-19

      Great article on an upcoming testing technology:

      https://sponsored.bloomberg.com/news/sponsors/features/next-tech-stock/the-next-big-thing-in-health-tech/?adv=33197&prx_t=wmcGAAAAAAUk0NA&prx_ro=s&sref=GS2dzBte



      👍️0
      whytestocks whytestocks 4 years ago
      Breaking News: $GSK Investors Wish They Could Vote These 2 Healthcare CEOs Out

      One of the best things about a democracy is getting to vote out representatives who let us down. As shareholders, it's much harder to express dissatisfaction in management without just selling shares, since you may really like the business despite management.  But some investors might ...

      Read the whole news GSK - Investors Wish They Could Vote These 2 Healthcare CEOs Out
      👍️0
      jondoeuk jondoeuk 4 years ago
      Decitabine has been shown to induce cancer-testis antigen expression https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0139221
      👍️0
      jondoeuk jondoeuk 4 years ago
      SITC

      Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo

      Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers

      Final analysis of the Phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS)
      👍️0
      jondoeuk jondoeuk 4 years ago
      Going forward, I would like them to transduce half of the CD4+ T-cells with an NY-ESO-1 specific MHC II restricted TCR [1], and the other half to co-express a CD8a. Combining both CD4+ and CD8+ can induce bystander killing of antigen-negative cancer cells [2,3]. Also, some of the CD4+ can show tumoricidal activity by their own means irrespective of MHC II expression [4-7].

      Refs:
      1 https://www.nejm.org/doi/full/10.1056/nejmoa0800251
      2 https://rupress.org/jem/article/207/11/2469/40645/Bystander-killing-of-cancer-requires-the
      3 https://www.nature.com/articles/srep14896
      4 https://cancerres.aacrjournals.org/content/70/21/8368.long
      5 https://rupress.org/jem/article/154/3/952/49262/Eradication-of-disseminated-murine-leukemia-by
      6 https://rupress.org/jem/article/207/3/637/40473/Tumor-reactive-CD4-T-cells-develop-cytotoxic
      7 https://www.cell.com/immunity/fulltext/S1074-7613(00)80218-6
      👍️0
      jondoeuk jondoeuk 4 years ago
      Lyell plan to use defined cell populations [1], improve ex vivo expansion [2-4], and a novel co-stim [5].

      Refs:
      1 https://www.nature.com/articles/leu2015247
      2 https://www.sciencedirect.com/science/article/abs/pii/S1535610820302543
      3 https://cancerres.aacrjournals.org/content/75/2/296.long
      4 https://link.springer.com/article/10.1007%2Fs00262-012-1378-2
      5 https://www.nature.com/articles/s41586-019-1805-z
      👍️0
      jondoeuk jondoeuk 4 years ago
      Hopefully, trials testing these improvements will start early next year https://www.fiercebiotech.com/biotech/gsk-taps-lyell-immunopharma-to-take-cell-therapy-to-next-level
      👍️0
      jondoeuk jondoeuk 4 years ago
      A new trial testing the NY-ESO-1 TCR-T cell therapy product [1] which either co-expresses a CD8a [2] or dnTGFßRII [2].

      Refs:
      1 https://clinicaltrials.gov/ct2/show/NCT04526509
      2 (Some of the R&D was conducting with ADAP) https://www.adaptimmune.com/our-company/perspectives/detail/1153/jon-silk-talks-about-our-next-generation-research
      👍️0
      MustBeTheTruth MustBeTheTruth 5 years ago
      Better Development Tools for a New Golden Era of Psychopharmacology

      https://www.thecannabisinvestor.ca/better-development-tools-for-a-new-golden-era-of-psychopharmacology/
      👍️0
      T695 T695 5 years ago
      Calls might sky rocket tomorrow
      👍️0
      T695 T695 5 years ago
      Calls for next month
      👍️0
      BottomBounce BottomBounce 5 years ago
      Trump promises Cincinnati rally that US will end AIDS epidemic and find a cure for childhood cancer 'very shortly'

      https://www.businessinsider.com/trump-cincinnati-promises-cure-cancer-and-aids-very-shortly-2019-8
      👍️0
      BottomBounce BottomBounce 5 years ago
      $GSK Democratic-run House approves its $3 trillion relief measure in vote late Friday https://www.marketwatch.com/story/next-coronavirus-aid-package-expected-to-become-reality-in-june-at-the-earliest-as-house-prepares-to-pass-its-bill-on-friday-2020-05-15?mod=mw_more_headlines
      👍️0
      BottomBounce BottomBounce 5 years ago
      Here's Why Investors Should Follow Sanofi $SNY and GlaxoSmithKline's $GSK New #Coronavirus #COVID19
      Collaboration


      https://www.fool.com/investing/2020/04/30/heres-why-investors-should-follow-sanofi-and-glaxo.aspx
      👍️0
      BottomBounce BottomBounce 5 years ago
      **** BREAKING HIV $GSK <<<< Drug giant GSK today declared a major breakthrough on a new HIV treatment it was trialling in patients that could prevent the spread of the disease. https://www.standard.co.uk/business/drug-giant-gsk-sees-major-breakthrough-on-hiv-treatment-a4442996.html
      👍️0
      Nebuchadnezzar Nebuchadnezzar 5 years ago
      GSK-especially now in current market turmoil $35 looks XTRA tasty
      👍️0
      BottomBounce BottomBounce 5 years ago
      Sci-B-Vac data is in December. That's the drug beating $GSK's Engerix-B

      The infection prevention rate for $VBIV 91.4% for Sci-B-Vac

      The infection prevention rate for $GSK 76.5% for Engerix-B
      👍️0
      BottomBounce BottomBounce 5 years ago
      $VBIV VBI Vaccines will collaborate with GlaxoSmithKline ( $GSK -2.8%) in a Phase 1/2a clinical trial evaluating its therapeutic vaccine candidate VBI-1901 in patients with recurrent glioblastoma (GBM) (brain tumor). It plans to add an additional arm to the open-label study to assess the combination of VBI-1901 and Glaxo's AS01B adjuvant that it uses in its Shingrix shingles vaccine.

      Part B of the trial will now be two arms, one evaluating VBI-1901 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and the other with AS01B, in 20 first-recurrent GBM patients. Enrollment of the first 10 participants should be initiated next quarter.
      👍️0
      BottomBounce BottomBounce 5 years ago
      $VBIV VBI Vaccines will collaborate with GlaxoSmithKline ( $GSK ) in a Phase 1/2a clinical trial evaluating its therapeutic vaccine candidate VBI-1901 in patients with recurrent glioblastoma (GBM) (brain tumor). It plans to add an additional arm to the open-label study to assess the combination of VBI-1901 and Glaxo's AS01B adjuvant that it uses in its Shingrix shingles vaccine.

      Part B of the trial will now be two arms, one evaluating VBI-1901 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and the other with AS01B, in 20 first-recurrent GBM patients. Enrollment of the first 10 participants should be initiated next quarter.

      https://seekingalpha.com/news/3498284-vbi-vaccines-teams-glaxo-therapeutic-cancer-vaccine-shares-10-percent
      👍️0
      BottomBounce BottomBounce 5 years ago
      $GSK and $VBIV VBI Vaccines teams up with Glaxo on therapeutic cancer vaccine https://seekingalpha.com/news/3498284-vbi-vaccines-teams-glaxo-therapeutic-cancer-vaccine-shares-10-percent
      👍️0
      Robbinhood101 Robbinhood101 5 years ago
      Watch this one go up with Tesaro approval.
      👍️0
      I Need Money I Need Money 5 years ago
      Certainly a great LONG term hold. ;)
      👍️0
      Don'tDrinkTheKoolAid Don'tDrinkTheKoolAid 5 years ago
      YIKES haha nice up tick with a great divvy.
      👍️0
      I Need Money I Need Money 5 years ago
      $41.99 now. :)
      👍️0
      Don'tDrinkTheKoolAid Don'tDrinkTheKoolAid 6 years ago
      Yep 39 now with 5% divvy I don't own it now :(!
      👍️0
      DewDiligence DewDiligence 6 years ago
      GSK, PFE form consumer-health JV: #msg-145552190.
      👍️0
      Dhubbard5 Dhubbard5 6 years ago
      I agree with your theory completely make total sense.
      👍️0
      debunker1 debunker1 7 years ago
      Novartis' Entresto is nothing more than an attempt to extend the patent life of Diovan (Valsartan). There is nothing to prove that Entresto is any better than the now generically available Valsartan.

      👍️0
      Don'tDrinkTheKoolAid Don'tDrinkTheKoolAid 7 years ago
      Buy anything below 36 not much down side risk.
      👍️0

      Your Recent History

      NYSE
      GSK
      GSK
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads